$LRMR
Larimar Therapeutics, Inc.

2020 Q1 Form 10-K Financial Statement

#000156459020008984 Filed on March 05, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q4 2019 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.670M $5.320M $3.630M
YoY Change -54.25% 64.71% 8.68%
% of Gross Profit
Research & Development $5.010M $420.0K $5.260M
YoY Change -47.98% -96.34% -55.54%
% of Gross Profit
Depreciation & Amortization $23.00K $70.00K $80.00K
YoY Change -54.9% 40.0% -27.27%
% of Gross Profit
Operating Expenses $3.563M $7.281M $12.91M
YoY Change -73.16% -50.44% -14.92%
Operating Profit -$3.563M
YoY Change -73.16%
Interest Expense $301.0K $30.00K $426.0K
YoY Change -39.8% -75.0% -10.32%
% of Operating Profit
Other Income/Expense, Net -$35.00K -$8.000K
YoY Change -121.21% -107.84%
Pretax Income -$6.670M -$7.250M -$12.91M
YoY Change -49.12% -50.24% -14.33%
Income Tax
% Of Pretax Income
Net Earnings -$6.674M -$7.251M -$12.91M
YoY Change 41.28% -50.23% -14.29%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$779.2K -$2.331M -$4.151M
COMMON SHARES
Basic Shares Outstanding 37.47M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q4 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $63.90M $44.06M $82.00M
YoY Change -38.97% -62.68% -35.85%
Cash & Equivalents $887.0K $1.009M $5.515M
Short-Term Investments $24.90M $43.05M $38.70M
Other Short-Term Assets $600.0K $1.000M $1.200M
YoY Change -53.85% -41.18% -50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $64.68M $4.750M $83.40M
YoY Change -39.83% -96.09% -36.56%
LONG-TERM ASSETS
Property, Plant & Equipment $743.0K $274.0K $8.100M
YoY Change -38.08% -26.93% 1833.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $12.00K $90.00K $1.400M
YoY Change -78.95% 57.89% 2356.14%
Total Long-Term Assets $9.022M $451.0K $9.500M
YoY Change 236.01% 4.4% 1895.8%
TOTAL ASSETS
Total Short-Term Assets $64.68M $4.750M $83.40M
Total Long-Term Assets $9.022M $451.0K $9.500M
Total Assets $73.70M $5.201M $92.90M
YoY Change -33.11% -95.73% -29.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $322.0K $3.539M $3.300M
YoY Change -89.8% -1.42% 25.62%
Accrued Expenses $881.0K $2.259M $5.700M
YoY Change -73.3% -46.98% 16.3%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $7.300M $7.300M $7.300M
YoY Change 0.0% 32.73% 102.78%
Total Short-Term Liabilities $9.900M $5.895M $16.34M
YoY Change -27.88% -55.7% 46.35%
LONG-TERM LIABILITIES
Long-Term Debt $6.700M $8.500M $10.20M
YoY Change -50.37% -44.08% -39.29%
Other Long-Term Liabilities $6.300M $6.500M $6.500M
YoY Change 950.0%
Total Long-Term Liabilities $13.00M $15.00M $16.70M
YoY Change -7.8% -1.32% -0.6%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.900M $5.895M $16.34M
Total Long-Term Liabilities $13.00M $15.00M $16.70M
Total Liabilities $22.96M $5.895M $33.00M
YoY Change -17.41% -79.31% 17.82%
SHAREHOLDERS EQUITY
Retained Earnings -$399.9M -$23.13M
YoY Change -93.41%
Common Stock $450.7M $22.44M
YoY Change -94.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.256M -$694.0K $1.897M
YoY Change
Total Liabilities & Shareholders Equity $73.70M $5.201M $92.89M
YoY Change -33.12% -95.73% -29.6%

Cashflow Statement

Concept 2020 Q1 2019 Q4 2019 Q3
OPERATING ACTIVITIES
Net Income -$6.674M -$7.251M -$12.91M
YoY Change 41.28% -50.23% -14.29%
Depreciation, Depletion And Amortization $23.00K $70.00K $80.00K
YoY Change -54.9% 40.0% -27.27%
Cash From Operating Activities -$8.921M -$9.800M -$7.730M
YoY Change -28.47% -17.23% -40.86%
INVESTING ACTIVITIES
Capital Expenditures $58.00K -$280.0K -$70.00K
YoY Change 2800.0% 2700.0% -12.5%
Acquisitions
YoY Change
Other Investing Activities $18.19M -$4.270M $15.67M
YoY Change 2145.68% -129.9% -133.09%
Cash From Investing Activities -$778.0K -$4.560M $15.60M
YoY Change -196.41% -131.98% -132.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.808M -1.760M -1.780M
YoY Change -2003.16% -200.0% -102.74%
NET CHANGE
Cash From Operating Activities -8.921M -9.800M -7.730M
Cash From Investing Activities -778.0K -4.560M 15.60M
Cash From Financing Activities -1.808M -1.760M -1.780M
Net Change In Cash -122.0K -16.12M 6.090M
YoY Change -98.95% -485.65% 38.1%
FREE CASH FLOW
Cash From Operating Activities -$8.921M -$9.800M -$7.730M
Capital Expenditures $58.00K -$280.0K -$70.00K
Free Cash Flow -$8.979M -$9.520M -$7.660M
YoY Change -28.01% -19.53% -41.03%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001374690
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019Q4 us-gaap Assets Current
AssetsCurrent
71503000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
821000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7051000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1339000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
57000
CY2018Q4 us-gaap Assets
Assets
121762000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3590000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4261000
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-12-31
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2019 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
68000
CY2018 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
25000
CY2019Q4 us-gaap Assets
Assets
80734000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
20000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
632000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1190000
CY2019Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
2709000
CY2018Q4 us-gaap Notes Payable Current
NotesPayableCurrent
5455000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
386000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13306000
CY2018Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
15185000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13193000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12160000
CY2019 us-gaap Revenues
Revenues
0
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23886000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47929000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16215000
CY2019 us-gaap Restructuring Charges
RestructuringCharges
5553000
CY2018 us-gaap Operating Expenses
OperatingExpenses
61122000
CY2017 us-gaap Operating Expenses
OperatingExpenses
52999000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-52999000
CY2017 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
22000
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
25000
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
22000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-52006000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2958000
CY2019 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-37000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43784000
CY2019 us-gaap Interest Expense
InterestExpense
1766000
CY2019 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
25000
CY2018 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-237000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
248000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
971000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-45406000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-61368000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-52028000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.90
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.90
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27433239
CY2017 us-gaap Revenues
Revenues
0
CY2019 us-gaap Operating Expenses
OperatingExpenses
45654000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-729000
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
312000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5261000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20781000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
49331000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
40777000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
1217000
CY2019 dei Entity Registrant Name
EntityRegistrantName
ZAFGEN, INC.
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37469596
CY2019Q2 dei Entity Public Float
EntityPublicFloat
40100000
CY2019 dei Entity File Number
EntityFileNumber
001-36510
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-3857670
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
3 Center Plaza
CY2019 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 610
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02108
CY2019 dei City Area Code
CityAreaCode
617
CY2019 dei Local Phone Number
LocalPhoneNumber
622-4003
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Security12b Title
Security12bTitle
Common Stock
CY2019 dei Trading Symbol
TradingSymbol
ZFGN
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27211000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49331000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
43050000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
68735000
CY2019Q4 zfgn Tax Incentive Receivable Current
TaxIncentiveReceivableCurrent
243000
CY2018Q4 zfgn Tax Incentive Receivable Current
TaxIncentiveReceivableCurrent
1536000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
999000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1728000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
121330000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
375000
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
7273000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12190000
CY2019Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8464000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6456000
CY2019Q4 us-gaap Liabilities
Liabilities
27110000
CY2018Q4 us-gaap Liabilities
Liabilities
28491000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
37000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
37000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
449903000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
444212000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-396351000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-350945000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
35000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-33000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
53624000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
93271000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
80734000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
121762000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2291000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
864000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
289000
CY2019Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1190000
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37446498
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37287221
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37446498
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37287221
CY2018 us-gaap Revenues
Revenues
0
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40839000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-45654000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-61122000
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
1989000
CY2018 us-gaap Investment Income Interest
InvestmentIncomeInterest
1889000
CY2017 us-gaap Investment Income Interest
InvestmentIncomeInterest
996000
CY2018 us-gaap Interest Expense
InterestExpense
1898000
CY2017 us-gaap Interest Expense
InterestExpense
165000
CY2017 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
140000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-246000
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.22
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37347199
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32228721
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
68000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45338000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-61343000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
121727000
CY2017 zfgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
195000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8301000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
78217000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
64410000
CY2018 zfgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
2360000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9627000
CY2019 zfgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
194000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5497000
CY2019 us-gaap Profit Loss
ProfitLoss
-45406000
CY2018 us-gaap Profit Loss
ProfitLoss
-61368000
CY2017 us-gaap Profit Loss
ProfitLoss
-52028000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
5497000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
9627000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
8301000
CY2017 us-gaap Paid In Kind Interest
PaidInKindInterest
13000
CY2019 us-gaap Depreciation
Depreciation
263000
CY2018 us-gaap Depreciation
Depreciation
261000
CY2017 us-gaap Depreciation
Depreciation
188000
CY2019 us-gaap Asset Impairment Charges
AssetImpairmentCharges
80000
CY2019 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-20000
CY2019 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-5000
CY2018 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-76000
CY2017 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
46000
CY2019 zfgn Premium On Marketable Securities
PremiumOnMarketableSecurities
69000
CY2018 zfgn Premium On Marketable Securities
PremiumOnMarketableSecurities
6000
CY2017 zfgn Premium On Marketable Securities
PremiumOnMarketableSecurities
359000
CY2019 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
788000
CY2018 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
670000
CY2017 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-246000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-199000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
569000
CY2019 zfgn Increase Decrease In Tax Incentives Receivable
IncreaseDecreaseInTaxIncentivesReceivable
-1288000
CY2018 zfgn Increase Decrease In Tax Incentives Receivable
IncreaseDecreaseInTaxIncentivesReceivable
666000
CY2017 zfgn Increase Decrease In Tax Incentives Receivable
IncreaseDecreaseInTaxIncentivesReceivable
553000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
432000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
448000
CY2019 us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
2709000
CY2019 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2190000
CY2018 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
628000
CY2017 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
575000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40783000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
108000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-51487000
CY2019 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
109471000
CY2018 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
110388000
CY2017 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
150213000
CY2018Q4 us-gaap Notes Payable
NotesPayable
20000000
CY2019 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
82861000
CY2018 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
117147000
CY2017 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
114511000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
764000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
55000
CY2019 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
3000
CY2019 us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
586000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
25263000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6867000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
35647000
CY2017 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
20000000
CY2019 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
5455000
CY2017 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3633000
CY2019 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
194000
CY2018 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2360000
CY2017 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
195000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
64860000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
66908000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16562000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8554000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8425000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
32352000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28550000
CY2018 zfgn Public Offering Cost Included In Accounts Payable
PublicOfferingCostIncludedInAccountsPayable
138000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
6817000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
1144000
CY2017 us-gaap Interest Paid Net
InterestPaidNet
141000
CY2019Q4 zfgn Long Term Notes Payable Before Accretion
LongTermNotesPayableBeforeAccretion
7272000
CY2018Q4 zfgn Long Term Notes Payable Before Accretion
LongTermNotesPayableBeforeAccretion
14545000
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company&#8217;s estimates. </p>
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk and of Significant Suppliers </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company has all cash, cash equivalents and marketable securities balances at accredited financial institutions in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs, if and when development programs are active. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs. </p>
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.000
CY2019Q4 us-gaap Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid
DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
1192000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-45205000
CY2018Q4 us-gaap Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid
DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
640000
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
7273000
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
7272000
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
14545000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5497000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-58708000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9627000
CY2019 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2005-11-22
CY2019 zfgn Restructuring And Other Attrition Number Of Positions Eliminated Period Percent
RestructuringAndOtherAttritionNumberOfPositionsEliminatedPeriodPercent
0.70
CY2019Q4 zfgn Merger Agreement Minimum Required Net Cash Thresholds
MergerAgreementMinimumRequiredNetCashThresholds
30000000
zfgn Net Proceeds From Sale Of Securities
NetProceedsFromSaleOfSecurities
397900000
CY2019Q4 zfgn Line Of Credit Facility Debt Default Minimum Amount
LineOfCreditFacilityDebtDefaultMinimumAmount
300000
CY2019Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
70300000
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
100000
CY2019 zfgn Likelihood Percentage Minimum
LikelihoodPercentageMinimum
0.50
CY2019Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
22434000
CY2019Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
65484000
CY2018Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
45210000
CY2018Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
113945000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
43015000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
35000
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
68767000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
35000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1564000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
925000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
743000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
550000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
37000
CY2018Q4 zfgn Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1526000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
221000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
223000
CY2018Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
4261000
CY2017Q4 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
20000000
CY2019Q4 us-gaap Notes Payable
NotesPayable
14545000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-49954000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.041
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.652
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-201000
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.042
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.041
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-2660000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-2074000
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.047
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.002
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8301000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4013843
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5024371
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4494201
CY2019 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
100000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1090000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1120000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1143000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1165000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1189000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
5396000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
11103000
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4261000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
6842000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
464000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
226000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
690000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
971000
CY2019 us-gaap Short Term Lease Cost
ShortTermLeaseCost
185000
CY2019 us-gaap Sublease Income
SubleaseIncome
112000
CY2019 us-gaap Lease Cost
LeaseCost
1044000
CY2018 us-gaap Lease Cost
LeaseCost
400000
CY2017 us-gaap Lease Cost
LeaseCost
300000
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y5M26D
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.111
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
409000
CY2019Q4 zfgn Milestone Liability
MilestoneLiability
0
CY2018Q4 zfgn Milestone Liability
MilestoneLiability
0
CY2017Q4 zfgn Milestone Liability
MilestoneLiability
0
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-45406000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-61368000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-52028000
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.037
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.024
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.055
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.051
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.015
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
-0.001
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
-0.009
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
-0.014
CY2017 zfgn Valuation Allowance Deferred Tax Asset Change In Amount Decrease
ValuationAllowanceDeferredTaxAssetChangeInAmountDecrease
10039000
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.000
CY2019 zfgn Valuation Allowance Deferred Tax Asset Change In Amount Increase
ValuationAllowanceDeferredTaxAssetChangeInAmountIncrease
10887000
CY2018 zfgn Valuation Allowance Deferred Tax Asset Change In Amount Increase
ValuationAllowanceDeferredTaxAssetChangeInAmountIncrease
14011000
CY2019 zfgn Operating Loss Carryforwards Minimum Percentage Of Taxable Income In Tax Period
OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod
0.80
CY2019 us-gaap Restructuring And Related Cost Incurred Cost
RestructuringAndRelatedCostIncurredCost
5473000
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.000
CY2019Q1 us-gaap Revenues
Revenues
0
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
12906000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.012
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.240
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.229
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.288
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2019Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
65994000
CY2018Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
58832000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
19763000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
16728000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
21202000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
19331000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements
2122000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements
1918000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3242000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4371000
CY2019Q4 zfgn Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities Noncurrent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesNoncurrent
276000
CY2018Q4 zfgn Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities Noncurrent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesNoncurrent
493000
CY2019Q4 zfgn Deferred Tax Assets Other Noncurrent
DeferredTaxAssetsOtherNoncurrent
18000
CY2018Q4 zfgn Deferred Tax Assets Other Noncurrent
DeferredTaxAssetsOtherNoncurrent
19000
CY2019Q4 zfgn Deferred Tax Assets Operating Lease Liability Noncurrent
DeferredTaxAssetsOperatingLeaseLiabilityNoncurrent
1752000
CY2019Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
114369000
CY2018Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
101692000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
114369000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
101692000
CY2019Q4 zfgn Deferred Tax Liabilities Operating Lease Right Of Use Assets Noncurrent
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssetsNoncurrent
1790000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
112579000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
101692000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
87681000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
97720000
CY2019 us-gaap Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
carryforwards are limited to 80% of the taxable income in any one tax period.
CY2019Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2018Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2019Q4 zfgn Deferred Tax Assets Net Of Liabilities Before Valuation Allowance
DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance
112600000
CY2018Q4 zfgn Deferred Tax Assets Net Of Liabilities Before Valuation Allowance
DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance
101700000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.03
CY2019 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
20
CY2019 us-gaap Payments For Restructuring
PaymentsForRestructuring
2764000
CY2019Q2 us-gaap Revenues
Revenues
0
CY2019Q3 us-gaap Revenues
Revenues
0
CY2019Q4 us-gaap Revenues
Revenues
0
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
13277000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
12190000
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
7281000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-13112000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-12129000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-12914000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-7251000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37313947
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37326853
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37369829
CY2019Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37377223
CY2018Q1 us-gaap Revenues
Revenues
0
CY2018Q2 us-gaap Revenues
Revenues
0
CY2018Q3 us-gaap Revenues
Revenues
0
CY2018Q4 us-gaap Revenues
Revenues
0
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
15702000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
15560000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
15169000
CY2018Q4 us-gaap Operating Expenses
OperatingExpenses
14691000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-15956000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-15775000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-15067000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-14570000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.58
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.57
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27541594
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27565064
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36619575
CY2018Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37036065

Files In Submission

Name View Source Status
0001564590-20-008984-index-headers.html Edgar Link pending
0001564590-20-008984-index.html Edgar Link pending
0001564590-20-008984.txt Edgar Link pending
0001564590-20-008984-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zfgn-10k_20191231.htm Edgar Link pending
zfgn-20191231.xml Edgar Link completed
zfgn-20191231.xsd Edgar Link pending
zfgn-20191231_cal.xml Edgar Link unprocessable
zfgn-20191231_def.xml Edgar Link unprocessable
zfgn-20191231_lab.xml Edgar Link unprocessable
zfgn-20191231_pre.xml Edgar Link unprocessable
zfgn-ex1028_415.htm Edgar Link pending
zfgn-ex1035_169.htm Edgar Link pending
zfgn-ex211_81.htm Edgar Link pending
zfgn-ex231_7.htm Edgar Link pending
zfgn-ex311_6.htm Edgar Link pending
zfgn-ex312_8.htm Edgar Link pending
zfgn-ex321_9.htm Edgar Link pending
zfgn-ex43_80.htm Edgar Link pending